Economic considerations for the use of recombinant human bone morphogenetic protein-2 in open tibial fractures in Europe: The German model

Current Medical Research and Opinion, Supplement

Volumn 22, Issue 1, 2006, Pages

  Alt, Volker ^a   Heissel, A ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b AMGEN INC   (United States)

Author keywords

Economic model; Health economics; RhBMP 2

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT PROTEIN;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EUROPE; FRACTURE HEALING; FRACTURE NONUNION; GERMANY; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INFECTION RATE; MEDICAL LEAVE; REVIEW; STATISTICAL MODEL; TIBIA FRACTURE; TREATMENT OUTCOME;

BONE MORPHOGENETIC PROTEINS; COST-BENEFIT ANALYSIS; DRUG COSTS; EUROPE; GERMANY; HUMANS; RECOMBINANT PROTEINS; TIBIAL FRACTURES; TRANSFORMING GROWTH FACTOR BETA;

EID: 33748053020     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80602     Document Type: Review

References (13)

1. Szucs T. Economic evaluation of technologies in health care. In: Szucs T, Haverich A, Odar J, editors. Economics of surgical procedures. Heidelbergand: JA Earth, 2000. pp.3-4
2. Hunink, M, Glasziou P, Siegel, et al. Decision making in health and medicine - integrating evidence and values. Cambridge: Cambridge University Press, 2001. p.245
3. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation in health care programmes, 2nd edn. New-York: Oxford University Press, 1997. p.17ff
4. Neumann PJ. Using cost-effectiveness analysis to improve health care. Opportunities and barriers. New York: Oxford University Press, 2005. pp.95, 103-106ff
5. Malik MH, Harwood P, Diggle P, et al. Factors affecting rates of infection and nonunion in intramedullary nailing. J Bone Joint Surg Br 2004;86:556-60
6. Heckman JD, Sarasohn-Kahn J. The economics of treating tibia fractures. The cost of delayed unions. Bull Hosp Jt Dis 1997;56:63-72
7. ten Dijke P. Bone morphogenetic protein signal transduction in bone. Curr Med Res Opin 2006;22(suppl 1):S7
8. Govender S, Csimma C, Genant HK, et al., the BMP-2 Evaluation in Surgery for Tibial Trauma (BESH) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures. A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surgery 2002;84-A:2123-34
9. Ackerman SJ, Mafilios MS, Polly DW Jr. Economic evaluation of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion: an evidence-based modeling approach. Spine 2002;27(Suppl 1):S94-9
10. Polly DW Jr, Ackerman SJ, Shaffrey CI, et al. A cost analysis of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion. Orthopedics 2003;26:1027-37
11. German Ministry of Health. Results of public health insurers 2004. Table KJ 1. Berlin, Germany: Ministry of Health
12. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty five open fractures of long bones. Retrospective and prospective analysis. J Bone Joint Surg 1976;58:453-8
13. Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures. A new classification of type III open fractures. J Trauma 1984;24:742-6